Emerging therapies for eosinophilic esophagitis

Thomas Greuter, Ikuo Hirano, Evan S. Dellon*

*Corresponding author for this work

Research output: Contribution to journalArticle

Abstract

Despite advances in the pathologic understanding of eosinophilic esophagitis (EoE), as of yet, no single agent has been approved by the US Food and Drug Administration to treat EoE. Off-label, EoE is currently treated by using the 3 Ds: drugs (particularly swallowed topical corticosteroids), dietary restriction, and endoscopic dilation. In the recent past, considerable progress in terms of EoE treatment has been made: (1) new EoE-specific steroid formulations optimizing mucosal deposition have been developed, which has culminated in recent approval of a budesonide effervescent tablet in Europe; (2) biologics used for other TH2-mediated diseases, such as allergic asthma and atopic eczema, as well as purpose-developed biologics, have been studied in phase II trials in patients with EoE; and (3) novel dietary restriction strategies have evolved. Finally, further insights into the pathogenesis of EoE have revealed several novel disease mediators that might be targeted in the future. In the following article we will discuss recent advances in EoE treatment with regard to swallowed topical steroids, biological agents, dietary approaches, and novel molecular targets.

Original languageEnglish (US)
Pages (from-to)38-45
Number of pages8
JournalJournal of Allergy and Clinical Immunology
Volume145
Issue number1
DOIs
StatePublished - Jan 2020

Fingerprint

Eosinophilic Esophagitis
Therapeutics
Biological Products
Steroids
Budesonide
Biological Factors
United States Food and Drug Administration
Atopic Dermatitis
Tablets
Dilatation
Adrenal Cortex Hormones
Asthma

Keywords

  • Eosinophilic esophagitis
  • biologics
  • diet
  • steroids
  • treatment

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Greuter, Thomas ; Hirano, Ikuo ; Dellon, Evan S. / Emerging therapies for eosinophilic esophagitis. In: Journal of Allergy and Clinical Immunology. 2020 ; Vol. 145, No. 1. pp. 38-45.
@article{5673e08ce9ae43e08475d25c106db1de,
title = "Emerging therapies for eosinophilic esophagitis",
abstract = "Despite advances in the pathologic understanding of eosinophilic esophagitis (EoE), as of yet, no single agent has been approved by the US Food and Drug Administration to treat EoE. Off-label, EoE is currently treated by using the 3 Ds: drugs (particularly swallowed topical corticosteroids), dietary restriction, and endoscopic dilation. In the recent past, considerable progress in terms of EoE treatment has been made: (1) new EoE-specific steroid formulations optimizing mucosal deposition have been developed, which has culminated in recent approval of a budesonide effervescent tablet in Europe; (2) biologics used for other TH2-mediated diseases, such as allergic asthma and atopic eczema, as well as purpose-developed biologics, have been studied in phase II trials in patients with EoE; and (3) novel dietary restriction strategies have evolved. Finally, further insights into the pathogenesis of EoE have revealed several novel disease mediators that might be targeted in the future. In the following article we will discuss recent advances in EoE treatment with regard to swallowed topical steroids, biological agents, dietary approaches, and novel molecular targets.",
keywords = "Eosinophilic esophagitis, biologics, diet, steroids, treatment",
author = "Thomas Greuter and Ikuo Hirano and Dellon, {Evan S.}",
year = "2020",
month = "1",
doi = "10.1016/j.jaci.2019.10.027",
language = "English (US)",
volume = "145",
pages = "38--45",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",
number = "1",

}

Emerging therapies for eosinophilic esophagitis. / Greuter, Thomas; Hirano, Ikuo; Dellon, Evan S.

In: Journal of Allergy and Clinical Immunology, Vol. 145, No. 1, 01.2020, p. 38-45.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Emerging therapies for eosinophilic esophagitis

AU - Greuter, Thomas

AU - Hirano, Ikuo

AU - Dellon, Evan S.

PY - 2020/1

Y1 - 2020/1

N2 - Despite advances in the pathologic understanding of eosinophilic esophagitis (EoE), as of yet, no single agent has been approved by the US Food and Drug Administration to treat EoE. Off-label, EoE is currently treated by using the 3 Ds: drugs (particularly swallowed topical corticosteroids), dietary restriction, and endoscopic dilation. In the recent past, considerable progress in terms of EoE treatment has been made: (1) new EoE-specific steroid formulations optimizing mucosal deposition have been developed, which has culminated in recent approval of a budesonide effervescent tablet in Europe; (2) biologics used for other TH2-mediated diseases, such as allergic asthma and atopic eczema, as well as purpose-developed biologics, have been studied in phase II trials in patients with EoE; and (3) novel dietary restriction strategies have evolved. Finally, further insights into the pathogenesis of EoE have revealed several novel disease mediators that might be targeted in the future. In the following article we will discuss recent advances in EoE treatment with regard to swallowed topical steroids, biological agents, dietary approaches, and novel molecular targets.

AB - Despite advances in the pathologic understanding of eosinophilic esophagitis (EoE), as of yet, no single agent has been approved by the US Food and Drug Administration to treat EoE. Off-label, EoE is currently treated by using the 3 Ds: drugs (particularly swallowed topical corticosteroids), dietary restriction, and endoscopic dilation. In the recent past, considerable progress in terms of EoE treatment has been made: (1) new EoE-specific steroid formulations optimizing mucosal deposition have been developed, which has culminated in recent approval of a budesonide effervescent tablet in Europe; (2) biologics used for other TH2-mediated diseases, such as allergic asthma and atopic eczema, as well as purpose-developed biologics, have been studied in phase II trials in patients with EoE; and (3) novel dietary restriction strategies have evolved. Finally, further insights into the pathogenesis of EoE have revealed several novel disease mediators that might be targeted in the future. In the following article we will discuss recent advances in EoE treatment with regard to swallowed topical steroids, biological agents, dietary approaches, and novel molecular targets.

KW - Eosinophilic esophagitis

KW - biologics

KW - diet

KW - steroids

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=85075516527&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075516527&partnerID=8YFLogxK

U2 - 10.1016/j.jaci.2019.10.027

DO - 10.1016/j.jaci.2019.10.027

M3 - Article

C2 - 31705907

AN - SCOPUS:85075516527

VL - 145

SP - 38

EP - 45

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 1

ER -